CN114502594A - 牵涉施用抗-ccr5受体试剂的用于治疗或预防癌症的方法 - Google Patents

牵涉施用抗-ccr5受体试剂的用于治疗或预防癌症的方法 Download PDF

Info

Publication number
CN114502594A
CN114502594A CN202080069162.4A CN202080069162A CN114502594A CN 114502594 A CN114502594 A CN 114502594A CN 202080069162 A CN202080069162 A CN 202080069162A CN 114502594 A CN114502594 A CN 114502594A
Authority
CN
China
Prior art keywords
antibody
ccr5
lelimumab
binding fragment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080069162.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·伯格
S·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytodyn Inc
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of CN114502594A publication Critical patent/CN114502594A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202080069162.4A 2019-08-02 2020-07-31 牵涉施用抗-ccr5受体试剂的用于治疗或预防癌症的方法 Pending CN114502594A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962882353P 2019-08-02 2019-08-02
US62/882,353 2019-08-02
US202063047693P 2020-07-02 2020-07-02
US63/047,693 2020-07-02
PCT/US2020/044616 WO2021026028A1 (en) 2019-08-02 2020-07-31 Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents

Publications (1)

Publication Number Publication Date
CN114502594A true CN114502594A (zh) 2022-05-13

Family

ID=72193578

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080069162.4A Pending CN114502594A (zh) 2019-08-02 2020-07-31 牵涉施用抗-ccr5受体试剂的用于治疗或预防癌症的方法

Country Status (9)

Country Link
US (1) US20220298249A1 (https=)
EP (1) EP4007603A1 (https=)
JP (1) JP2022542524A (https=)
CN (1) CN114502594A (https=)
AU (1) AU2020324948A1 (https=)
BR (1) BR112022001037A2 (https=)
CA (1) CA3146474A1 (https=)
MX (1) MX2022001411A (https=)
WO (1) WO2021026028A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532019A (ja) * 2020-06-23 2023-07-26 マドン アドバイザーズ エルエルシー 抗ｃｃｒ５モノクローナル抗体ベースの組成物および方法
WO2025250666A1 (en) * 2024-05-29 2025-12-04 Cytodyn, Inc. Methods of treating cancer and inflammation-related diseases with leronlimab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
MX2008014296A (es) * 2006-06-12 2009-03-06 Pfizer Prod Inc Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih.
CA2939464A1 (en) * 2014-02-18 2015-08-27 Cytodyn Inc. Use of anti-ccr5 antibodies in graft versus host disease
CN107847514A (zh) 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
US20190016810A1 (en) * 2017-05-11 2019-01-17 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANIELA ET AL: "CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene-Transformed Metastatic Prostate Cancer Cell Lines", CANCER RES, vol. 74, no. 23, pages 7013 - 14 *
MARCO ET AL: "CCR5 antagonist blocks metastasis of basal breast cancer cells", CANCER RES, vol. 72, no. 15, pages 3839 - 3850, XP002752332, DOI: 10.1158/0008-5472.CAN-11-3917 *
NIELS ET AL: "umoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients", CANCER CELL, vol. 29, pages 587 - 601 *
XUANMAO JIAO ET AL: "Abstract 2009: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellularinvasion and enhances cell death induced by DNA damaging chemotherapies", CANCER RESEARCH, vol. 79, pages 2009 *

Also Published As

Publication number Publication date
BR112022001037A2 (pt) 2022-06-07
EP4007603A1 (en) 2022-06-08
JP2022542524A (ja) 2022-10-04
WO2021026028A1 (en) 2021-02-11
CA3146474A1 (en) 2021-02-11
AU2020324948A1 (en) 2022-02-17
MX2022001411A (es) 2022-03-25
US20220298249A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US10106616B2 (en) Antagonist antibodies to human prolactin receptor (PRLR)
JP2020072726A (ja) ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン
US11390684B2 (en) IgE antibodies for the inhibition of tumor metastasis
CN114502594A (zh) 牵涉施用抗-ccr5受体试剂的用于治疗或预防癌症的方法
US20190016810A1 (en) Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
KR20230159823A (ko) Cd112r에 대한 항체 및 이의 용도
JP7583736B2 (ja) 癌転移をブロックまたはｄｎａ損傷化学療法によって誘導される細胞死を増強する抗ｃｃｒ５薬剤および処置の方法
KR20220127859A (ko) Ccr5 양성 전이성 암 치료를 위한 ccr5 결합제
JP2025523501A (ja) Ｎａｆｌｄおよびｎａｓｈを処置する方法
WO2026076282A1 (en) Antagonistic interleukin-6 chimeric proteins
TW202430214A (zh) Cd47阻斷劑及抗bcma/抗cd3雙特異性抗體之組合療法
JP2013519689A (ja) 慢性炎症状態の治療

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220513

WD01 Invention patent application deemed withdrawn after publication